Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 535 results for "ranbaxy"

Ranbaxy integration, USFDA alert will hit Sun Pharma's revenue: Dilip Shanghvi

Ranbaxy integration, USFDA alert will hit Sun Pharma's revenue...

Shanghvi says remediation process at the erstwhile Ranbaxy facilities, which were found to be non-compliant in the past, continues as per plan, but it is a time-consuming process A file photo of Sun Pharma managing director Dilip Shanghvi. Photo: ..., 3 weeks ago
Ranbaxy Merger poses challenges for Sun Pharma Business Today India, 1 month ago
Sun Pharma ends patent dispute with Actavis, 1 month ago
Financial Express

Ranbaxy a difficult pill to swallow for Sun Pharma

ET INTELLIGENCE GROUP: Sun Pharma's acquisition of the beleaguered drug firm Ranbaxy in April 2014 just seemed right. Sun, with its experience in turning around distressed assets, was seen as the white knight for Ranbaxy. However, what appeared to ...
 Economic Times3 weeks ago Sun Pharma withdraws suit filed by Ranbaxy against USFDA  Financial Express1 month ago
Business Today India

Sun Pharma to sell Ranbaxy's two CNS units to Strides Arcolab for Rs 165 cr

Sun Pharmaceutical Industries is selling erstwhile Ranbaxy's two divisions in central nervous system (CNS) segment in India to Strides Arcolab for Rs 165 crore. "Sun Pharma and Strides have entered into a definitive agreement related to erstwhile ...
 Business Today India2 months ago Sun Pharma sells Ranbaxy divisions to Strides Arcolab for Rs1,65 crore  Livemint.com2 months ago Sun Pharma sells divisions of Ranbaxy to Strides Arcolab for Rs 165 crore  Times of India2 months ago Sun to sell Ranbaxy's 2 divisions to Strides for Rs 165 cr  Moneycontrol.com2 months ago

Sun Pharma Seeks Potential in Punjab

In focus to bring Ranbaxy facilities to compliance, Sun Pharma sees immense opportunities for expanding its operations in Punjab. According to Dilip Shanghvi, MD, Sun Pharma while addressing Investors Summit said that the company has aggressive ...
 EHealth Magazine3 weeks ago Sun Pharma sees huge expansion opportunities in Punjab  Economic Times4 weeks ago SUMMIT-SUNPHARMA - Sun Pharma sees huge expansion opportunities in Punjab  Namibia Press Agency4 weeks ago
Financial Express

Ranbaxy integration: Sun Pharma may drop some non-strategic units

NEW DELHI: Sun Pharma may discontinue certain non-strategic businesses as part of its integration process with Ranbaxy Laboratories, which it acquired in a $4 billion deal last year. The Mumbai-based firm also expects its revenues and net profit ...
 Economic Times3 weeks ago Ranbaxy integration: Sun may drop some non-strategic units  The Echo Of India3 weeks ago Ranbaxy integration: Sun may drop some non-strategic units  The Freepress Journal3 weeks ago

Ranbaxy woes continue to dog Sun Pharma

Related to : Sun Pharmaceuticals Industries Ltd Sun Pharmaceuticals Industries Ltd BSE 28 Oct 15 | 12:00 AM 901.00 -4.45 (-0.49%) NSE 28 Oct 15 | 12:00 AM 901.55 -7.1 (-0.78%) Sun Pharmaceutical Industries has initiated a recall ...
 Smart Investor4 weeks ago Sun Pharma pulls 1 million boxes of generic Claritin in further Ranbaxy cleanup  FiercePharma4 weeks ago Sun recalls 1M-plus boxes of generic Claritin made at Ohm Labs  FiercePharmaManufacturing4 weeks ago India's Sun Pharma reportedly plotting to snatch Japanese drug portfolio from Novartis  BioPharma Dive1 week ago
DNA India

India's Sun Pharma looks to exit nonstrategic businesses

India's Sun Pharmaceutical is still trying to digest its $4 billion acquisition of Ranbaxy , and Sun officials said at the company's annual general meeting this past week that it may exit some unidentified "nonstrategic" businesses as it works to ...
 FiercePharma3 weeks ago Sun Pharma to recall 10 lakh boxes of anti-allergy drug in US  DNA India4 weeks ago Sun Pharma recalls over 10 lakh boxes of allergy drug in US  DNA India4 weeks ago Column: A billion-dollar destination for Indian pharma exports  Financial Express6 days ago
Financial Express

Strides Arcolab shares gain on acquiring CNS divisions of Ranbaxy Laboratories

Last one week high and low of the scrip stood at Rs 1,196 and Rs 1,100.80 respectively. (Reuters) Strides Arcolab shares gained as much as 3.98 per cent on Monday after Sun Phamaceutical Industries and Strides Arcolab announced that they have ...
 Financial Express2 months ago Press Release Q2 FY16 INR  Noodls4 weeks ago Strides Arcolab to buy seven brands from J&J, part of Medispan  VC Circle1 month ago Stocks that made news today: Gujarat NRE Coke, Indian Overseas Bank and more  Financial Express1 month ago
Financial Express

Govt to commission study on impact of FDI in pharma

In 2008, Japanese firm Daiichi Sankyo had bought out the country's largest drug maker Ranbaxy for USD 4.6 billion.(Reuters) The government is likely to commission a study soon to assess the impact of foreign direct investment in existing ...
 Financial Express1 month ago Indian Government Decides to Assess the Impact of FDI in Pharma Companies  MedIndia1 month ago
DNA India

Ranbaxy valuation

3. Number of Shares of Sun Pharma (As on 31st March, 2013) 1035581955 Average Share Price (As on 31st December, 2012) 365.436 Value of Sun Pharma 3.78439E+11 Value of Ranbaxy 270461819875.16 As per our calculation 0.71 As per
 SlideShare.net3 weeks ago Sun Pharma drops wind energy plan; shares rise over 4%  DNA India1 hour ago Sun Pharma up 2%, Taro decides not to invest in wind energy  Moneycontrol.com5 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - ranbaxy
Get updated on latest news & your favorite topics right in your inbox!
More     Less